Trabectedin for inoperable or recurrent soft tissue sarcoma in adult patients: a retrospective cohort study

BMC Cancer
Fernando A AngaritaMartin E Blackstein

Abstract

Trabectedin is an antineoplastic agent used for patients with soft tissue sarcoma (STS) who fail standard-of-care treatment. Real-world data of its performance is scarce. This study evaluates the safety and effectiveness of trabectedin for patients with advanced STS who were treated at a high-volume sarcoma center. A retrospective chart review was performed on 77 patients treated with trabectedin (24 h infusion q3w) between 01/2005 and 05/2014. Data regarding safety, objective radiological response, progression-free and overall survival were analyzed. Median age at treatment onset was 52y [interquartile range (IQR): 45-61y]. Tumors included leiomyosarcoma (41.6%), liposarcoma (18.2%), and synovial sarcoma (13%). Trabectedin was provided as ≥ third-line chemotherapy in 71.4%. Median number of cycles was 2 (range: 1-17). Dose reduction and treatment delays occurred in 19.5 and 40.3%, respectively. Toxicities occurred in 78%, primarily for neutropenia or elevated liver enzymes. Two patients died secondary to trabectedin-induced rhabdomyolysis. Treatment was discontinued because of disease progression (84.7%), toxicity (10%), and patient preference (5%). Partial response or stable disease occurred in 14.1 and 33.8%, respectively, w...Continue Reading

References

Mar 7, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S DelalogeE Cvitkovic
Mar 7, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A TaammaE Cvitkovic
Dec 4, 2002·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·A T van OosteromUNKNOWN EORTC Soft Tissue and Bone Sarcoma Group
Mar 3, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A YovineJ L Misset
Apr 16, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R Garcia-CarboneroG D Demetri
Jan 22, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A Le CesneO S Nielsen
Aug 20, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R Garcia-CarboneroG D Demetri
Jul 13, 2007·Clinical Oncology : a Journal of the Royal College of Radiologists·R RoylanceJ Whelan
Aug 30, 2008·Therapeutics and Clinical Risk Management·Philippe A CassierJérôme Fayette
Dec 23, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E A EisenhauerJ Verweij
Feb 5, 2009·Molecular Cancer Therapeutics·Claudia ForniRoberto Mantovani
Feb 26, 2009·Natural Product Reports·Carmen Cuevas, Andrés Francesch
Oct 27, 2009·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Stefan SleijferJean-Yves Blay
Mar 11, 2010·Cancer Research·Giovanni GermanoPaola Allavena
Jul 22, 2010·Molecular Cancer Therapeutics·Maurizio D'Incalci, Carlos M Galmarini
Feb 16, 2013·Cancer Cell·Giovanni GermanoPaola Allavena
Jan 24, 2014·Future Oncology·Ioannis GounarisHelena M Earl
Sep 12, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·UNKNOWN ESMO/European Sarcoma Network Working Group
Feb 17, 2015·World Journal of Gastrointestinal Endoscopy·Joana MagalhãesJosé Cotter
Mar 3, 2015·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Axel Le CesneUNKNOWN French Sarcoma Group

❮ Previous
Next ❯

Citations

Jun 22, 2016·Expert Opinion on Pharmacotherapy·Rita De SanctisArmando Santoro
Sep 13, 2016·Expert Opinion on Pharmacotherapy·Ritika Zijoo, Margaret von Mehren
Dec 14, 2018·BMC Cancer·Anastasios KyriazoglouMeletios Athanasios Dimopoulos

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsies

Software Mentioned

SPSS

Related Concepts

Related Feeds

Cancer Incidence & Mortality

Cancer has emerged as a global concern due to its increase in incidence and mortality. Efforts are underway to evaluate and develop action plans to reduce the global burden of cancer. Currently, lung cancer, breast cancer and prostate cancer are the leading causes of cancer mortality. Here is the latest research on cancer incidence and mortality.

Related Papers

Journal of B.U.ON. : Official Journal of the Balkan Union of Oncology
U DemirciAnatolian Society of Medical Oncology (ASMO)
European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
Axel Le CesneFrench Sarcoma Group
© 2022 Meta ULC. All rights reserved